Search
Elebsiran
go.drugbank.com/drugs/DB19018InvestigationalElebsiran is under investigation in clinical trial NCT05461170 (SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.).
Olorofim
go.drugbank.com/drugs/DB15245InvestigationalOlorofim is under investigation in clinical trial NCT03340597 (Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects).
Centhaquine
go.drugbank.com/drugs/DB16122InvestigationalCenthaquine is under investigation in clinical trial NCT04045327 (Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock).
NVS antibody
go.drugbank.com/drugs/DB05312ExperimentalThis drug has been developed using Medarex's UltiMAb Human Antibody Development System to treat autoimmune diseases.
NSI-189
go.drugbank.com/drugs/DB16230InvestigationalNSI-189 is under investigation in clinical trial NCT02695472 (Study of NSI-189 for Major Depressive Disorder).
Lexanersen
go.drugbank.com/drugs/DB17933InvestigationalLexanersen is an antisense oligonucleotide under investigation for use as a disease-modifying therapy in Huntington's disease.
Synonyms: Dna, d(rgm-(p(s))-sp-rum-rgm-rcm-ram-(p(s))-sp-c-(p(s))-sp-a-(p(s))-sp-c-(p(s))-sp-a-(p(s))-sp-g-(p(s))-sp-t-(p(s))-sp-a-(p(s))-sp-g-(p(r))-sp-a-(p(s))-sp-t-(p(s))-sp-rgm-ram-rgm-rgm-(p(s))-sp-rgm)RTL-1000
go.drugbank.com/drugs/DB17946InvestigationalRTL-1000 is a recombinant T-Cell receptor ligand being investigated for the treatment of multiple sclerosis.
Synonyms: Recombinant t-cell receptor ligand rtl-1000, Rtl-1000 (recombinant t-cell receptor ligand)PARPI F-18
go.drugbank.com/drugs/DB18657ExperimentalPARPI F-18 is a diagnostic agent under investigation for use in the management of glioblastoma multiforme.
Canvuparatide
go.drugbank.com/drugs/DB18658InvestigationalCanvuparatide is a long-acting parathyroid hormone peptide prodrug under investigation for the treatment of hyperparathyroidism.[L48365]
Ivonescimab
go.drugbank.com/drugs/DB18931InvestigationalIvonescimab is under investigation in clinical trial NCT05184712 (Phase 3 Clinical Study of AK112 for NSCLC Patients).